GenMark Diagnostics, Inc. (NASDAQ:GNMK) CFO Scott Mendel sold 1,752 shares of the business’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $10.16, for a total transaction of $17,800.32. Following the transaction, the chief financial officer now owns 140,994 shares in the company, valued at approximately $1,432,499.04. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Scott Mendel also recently made the following trade(s):

  • On Wednesday, August 2nd, Scott Mendel sold 333 shares of GenMark Diagnostics stock. The shares were sold at an average price of $10.33, for a total transaction of $3,439.89.
  • On Friday, May 19th, Scott Mendel sold 2,135 shares of GenMark Diagnostics stock. The shares were sold at an average price of $12.89, for a total transaction of $27,520.15.

GenMark Diagnostics, Inc. (NASDAQ GNMK) traded down 0.99% on Tuesday, reaching $9.99. 205,246 shares of the company’s stock traded hands. The firm’s 50 day moving average price is $11.41 and its 200 day moving average price is $12.17. GenMark Diagnostics, Inc. has a 12 month low of $8.03 and a 12 month high of $13.67. The company’s market cap is $546.12 million.

GenMark Diagnostics (NASDAQ:GNMK) last announced its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.32) by $0.05. The firm had revenue of $12.36 million for the quarter, compared to analysts’ expectations of $12.44 million. GenMark Diagnostics had a negative net margin of 111.96% and a negative return on equity of 109.89%. The business’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.30) EPS. On average, equities analysts expect that GenMark Diagnostics, Inc. will post ($1.07) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/08/15/genmark-diagnostics-inc-gnmk-cfo-sells-17800-32-in-stock.html.

A number of research firms recently issued reports on GNMK. BidaskClub downgraded shares of GenMark Diagnostics from a “hold” rating to a “sell” rating in a research report on Monday. Needham & Company LLC reiterated a “buy” rating and set a $16.00 target price (up previously from $15.00) on shares of GenMark Diagnostics in a research report on Wednesday, May 3rd. ValuEngine upgraded shares of GenMark Diagnostics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Cowen and Company reiterated an “outperform” rating and set a $17.00 target price on shares of GenMark Diagnostics in a research report on Wednesday, August 2nd. Finally, BTIG Research restated a “buy” rating and set a $17.00 price objective on shares of GenMark Diagnostics in a report on Wednesday, May 17th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $15.80.

A number of institutional investors have recently made changes to their positions in the stock. Bellevue Group AG purchased a new position in shares of GenMark Diagnostics during the first quarter valued at approximately $4,008,000. Metropolitan Life Insurance Co. NY raised its position in shares of GenMark Diagnostics by 10.2% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 29,013 shares of the medical equipment provider’s stock valued at $355,000 after buying an additional 2,689 shares in the last quarter. MARSHALL WACE ASIA Ltd purchased a new position in shares of GenMark Diagnostics during the first quarter valued at approximately $375,000. Ameriprise Financial Inc. purchased a new position in shares of GenMark Diagnostics during the first quarter valued at approximately $435,000. Finally, Nationwide Fund Advisors raised its position in shares of GenMark Diagnostics by 3.9% in the first quarter. Nationwide Fund Advisors now owns 25,936 shares of the medical equipment provider’s stock valued at $332,000 after buying an additional 981 shares in the last quarter. 93.07% of the stock is owned by institutional investors and hedge funds.

About GenMark Diagnostics

GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.